Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial Meeting Abstract
| Authors: | Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; Hartley-Brown, M. A.; Lonial, S.; Campagnaro, E. L.; Voorhees, P. M.; Orlowski, R. Z.; Libby, E.; Hurd, D. D.; Costello, C. L.; Raje, N. S.; Medvedova, E.; McCarthy, P. L.; Milner, C. P.; Gasparetto, C.; Agha, M. E.; Gowin, K.; Kamble, R. T.; Jagannath, S.; Nathwani, N.; Alsina, M.; Giralt, S. A.; Laubach, J. P.; Nadeem, O.; Ghobrial, I. M.; Mo, C. C.; Samur, M. K.; Anderson, K. C.; Munshi, N. C.; Richardson, P. G. |
| Abstract Title: | Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 4762 |
| Language: | English |
| ACCESSION: | WOS:001159740308251 |
| DOI: | 10.1182/blood-2023-181032 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work